Basic Information
INFANRIX HEXA VACCINE
INJECTION
Regulatory Information
SIN12288P
May 7, 2003
Prescription Only
Therapeutic
INTRAMUSCULAR
August 10, 2023
June 3, 2025
XJ07CA09
Company Information
GLAXOSMITHKLINE PTE LTD
GLAXOSMITHKLINE PTE LTD
Active Ingredients
Strength: 10 mcg/0.5 ml
Strength: 10 mcg/0.5 ml
Strength: min 30 iu/0.5 ml
Strength: 8 mcg/0.5 ml
Strength: 40 du/0.5 ml
Strength: 25 mcg/0.5 ml
Strength: 25 mcg/0.5 ml
Strength: 32 du/0.5 ml
Strength: 8 du/0.5 ml
Detailed Information
Contraindications
**Contraindications** Hypersensitivity to the active substances or to any of the excipients or residues such as formaldehyde, neomycin and polymyxin (see _Qualitative and quantitative composition_ and _List of Excipients_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Hypersensitivity after previous administration of diphtheria, tetanus, pertussis, hepatitis B, polio or Hib vaccines. Infanrix hexa is contraindicated if the child has experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis-containing vaccine. In these circumstances, pertussis vaccination should be discontinued and the vaccination course should be continued with diphtheria-tetanus, hepatitis B, inactivated polio and Hib vaccines.
Indication Information
**Indications** Infanrix hexa is indicated for primary and booster vaccination of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and _Haemophilus influenzae_ type b. The use of Infanrix hexa should be in accordance with official recommendations.